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Summary
 
Susceptibility to multiple sclerosis is associated with the human histocompatibility leukocyte
antigen (HLA)-DR2 (DRB1*1501) haplotype. The structure of HLA-DR2 was determined
with a bound peptide from human myelin basic protein (MBP) that is immunodominant for
human MBP-specific T cells. Residues of MBP peptide that are important for T cell receptor
recognition are prominent, solvent exposed residues in the crystal structure. A distinguishing
feature of the HLA-DR2 peptide binding site is a large, primarily hydrophobic P4 pocket that
accommodates a phenylalanine of the MBP peptide. The necessary space for this aromatic side
chain is created by an alanine at the polymorphic DR
 
b
 
 71 position. These features make the P4
pocket of HLA-DR2 distinct from DR molecules associated with other autoimmune diseases.
Key words: HLA-DR2 • crystal structure • myelin basic protein • multiple sclerosis • 
autoimmunity
 
T
 
he MHC region on chromosome 6 represents an im-
portant susceptibility locus for a number of polygenic,
chronic inflammatory human diseases, such as type I diabe-
tes, rheumatoid arthritis, and multiple sclerosis (MS)
 
1
 
 (for re-
views see references 1–3). In the case of MS, the highest link-
age of disease scores within the MHC were obtained with
markers for the MHC class II region (4–6). Many previous
studies had demonstrated that the DR2 (DRB1*1501)
haplotype is present at an increased frequency in patients
with MS, in particular in patients of Scandinavian
descent who carry the highest risk. This haplotype in-
cludes the DRB1*1501, DRB5*0101, DQA1*0102, and
DQB1*0602 alleles that are in linkage disequilibrium; these
encode HLA-DR2b (DRA, DRB1*1501), HLA-DR2a
(DRA, DRB5*0101), and HLA-DQ6 (DQA1*0102,
DQB1*0602) (7–9). Disease-associated MHC alleles may
confer susceptibility by affecting T cell repertoire selection
in the thymus/peripheral immune system and/or by pre-
senting self-peptides against which an autoimmune re-
sponse is directed. The observation that particular alleles are
associated with a given autoimmune disease suggests that a
limited number of self-peptides are involved in early stages
of the disease process. In later stages of the disease, the au-
toimmune response may broaden to a larger set of anti-
gens/peptides (epitope spreading; reference 10).
The target antigens in MS are not known; major candi-
date antigens include myelin basic protein (MBP), proteo-
lipid protein, and myelin oligodendrocyte glycoprotein
(MOG). In experimental animal models of MS, central
nervous system inflammation and demyelination can be in-
duced by immunization with peptides representing immu-
nodominant T cell epitopes of these antigens or by transfer
of antigen-specific T cell clones (for review see reference
11). In addition, antibodies to MOG were shown to en-
hance demyelination after an inflammatory response had
been initiated by myelin-specific T cells (12, 13).
The analysis of the human immune response to myelin
antigens has focused primarily on human MBP. A peptide
from the middle region of human MBP (residues 84–102)
was found to be immunodominant for human MBP-spe-
cific T cells, in particular in patients with the HLA-DR2
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Abbreviations used in this paper:
 
 HA, hemagglutinin; MBP, myelin basic
protein; MS, multiple sclerosis.
 
Coordinates will be deposited in the Protein Data Bank (Brookhaven Na-
tional Laboratory, Upton, NY) and are available before their release by
E-mail (ksmith@rascal.med.harvard.edu).
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haplotype (14–16). MBP(85–99)-specific T cell clones from
patients with the HLA-DR2 haplotype were HLA-DR2b
(DRA, DRB1*1501) restricted and the peptide was found
to bind to purified HLA-DR2b (DRA, DRB1*1501) (17,
18). Val 89 and Phe 92 of the MBP(85–99) peptide were
identified as P1 and P4 anchor residues for HLA-DR2b
binding. The peptide also bound, with a lower affinity, to
HLA-DR2a (DRA, DRB5*0101), with Phe 92 identified
as the P1 anchor residue for binding to this MHC class II
molecule (17).
Several lines of evidence indicate that MBP-specific T
cells are activated and clonally expanded in MS patients.
First, 
 
hprt
 
2
 
 mutants reactive to MBP were obtained from
blood lymphocytes of MS patients but not control subjects
(19). The 
 
hprt
 
2
 
 
 
mutant frequency is higher in cells that
have undergone expansion in vivo. Clonal expansion of
MBP-specific T cells was also demonstrated by TCR se-
quence analysis of independent MBP-specific T cell clones
from MS patients (20, 21). In addition, T cells specific for
the MBP(85–99) peptide could be expanded from the
blood of MS patients but not control subjects by stimula-
tion with transfectants that expressed HLA-DR2 but not
costimulatory molecules; expansion after MHC/peptide
stimulation in the absence of costimulation is a characteris-
tic of memory T cells (22).
We have determined the crystal structure of HLA-DR2
(DRA, DRB1*1501) complexed with a peptide from hu-
man MBP. Peptide residues that were previously found to
be important for TCR recognition of the MBP peptide are
prominent, solvent exposed residues in the HLA-DR2/
MBP peptide crystal structure. HLA-DR2 is characterized
by a large, primarily hydrophobic P4 pocket, due to the
presence of alanine at the polymorphic DR
 
b
 
71 position.
The P4 pocket is occupied by a phenylalanine of the MBP
peptide that represents a major anchor residue for HLA-
DR2 binding.
 
Materials and Methods
 
Protein Expression and Purification.
 
HLA-DR2 (DRA, DRB1*
1501) was expressed in the Baculovirus system by replacing the
hydrophobic transmembrane regions of DR
 
a
 
 and DR
 
b
 
 with
leucine zipper dimerization domains from the transcription fac-
tors Fos and Jun (23). In the expression construct, the MBP(85–
99) peptide sequence was attached to the NH
 
2
 
 terminus of the
mature DR
 
b
 
 chain through a 16–amino acid linker, similar to the
strategy described by Kozono et al. (24). The protein was purified
from concentrated supernatants by affinity chromatography using
mAb L243. The leucine zipper dimerization domains were
cleaved from the assembled DR2–MBP peptide complex with
V8 protease and the protein was further purified by anion-
exchange HPLC.
 
Protein Crystallization.
 
For crystallization, DR2–MBP was buf-
fer exchanged to 50 mM Tris, pH 7.5, and concentrated to 10
mg/ml in Centricon 10 concentrators (Amicon, Beverly, MA).
Crystals were obtained at 18
 
8
 
C in 100 mM glycine, pH 3.5, and
15–18% polyethylene glycol (PEG) 6K. Microseeding was used
to improve the quality of the crystals. Crystals (0.3 
 
3 
 
0.2 
 
3 
 
0.1
mm) were harvested for 10–12 h in 30% PEG 6K and 100 mM
glycine, pH 3.5, and were prepared for liquid nitrogen cryo-
cooling by slowly transferring individual crystals to harvest buffer
containing 5, 10, and 15% ethylene glycol. The final cryopro-
tectant contained 30% PEG 6K, 15% ethylene glycol, and 100
mM glycine, pH 3.5. Crystals were then flash cooled in cryogenic
nitrogen gas for data collection.
 
Data Collection and Processing.
 
High-resolution data (15–2.6 Å)
were collected on beamline A1 at the Cornell High Energy Syn-
chrotron Source (CHESS, Ithaca, NY) (
 
l 5 
 
0.920 Å) using an
ADSC 1K CCD detector (0.5
 
8
 
 oscillations). Data were indexed
and integrated with DENZO (25) and scaled using SCALEPACK
(CCP4). Data collection statistics are shown in Table 1. DR2–
MBP crystallized in a tetragonal space group with unit cell di-
mensions 
 
a
 
 5 
 
b
 
 5 
 
95.403 Å, 
 
c
 
 5 
 
295.219 Å and two molecules
per asymmetric unit. Examination of systematic absences identi-
fied the space group as either P4
 
3
 
2
 
1
 
2 or P4
 
1
 
2
 
1
 
2.
 
Structure Determination and Refinement.
 
The structure was de-
termined by molecular replacement with the program AMoRe
(26) using the DR1/hemagglutinin (HA) structure as a search
model (27). Before molecular replacement, the HA peptide was
removed from the model and 13 polymorphic residues that are
different between DR1 and DR2 were changed to alanine. The
rotation search gave two different solutions that were related by
180
 
8
 
 and represent two noncrystallographically related molecules.
 
Table 1.
 
Data Collection and Refinement Statistics
 
Crystal space group P4
 
3
 
2
 
1
 
2
Cell parameters (Å)
 
a
 
 
 
5
 
 
 
b
 
 
 
5
 
 95.4; 
 
c
 
 
 
5
 
 295.2
Molecules per ASU 2
Data Processing
Resolution limit (Å) 2.6
Mosaicity (
 
8
 
) 0.48
 
R
 
merge
 
 (%) 8.8 (27.6)
Unique reflections 42589
Total reflections 263333
Completeness (%) 88.3 (83.1)
I/
 
s
 
23.5 (3.9)
Refinement
Data range (Å) 20.0–2.6
 
R
 
free
 
 (%) 26.6 (38.6)
 
R
 
cryst
 
 (%) 23.4 (37.7)
Residue Average B
Protein 768 35.6
Water 50 35.7
Root-mean-square-
deviations
Bonds (Å) 0.009
Angles (
 
8
 
) 1.5
B factors (Å
 
2
 
 bonded) 2.1
Numbers in parentheses indicate the specific value in the resolution
shell from 2.49 to 2.6 Å. A random 5% of reflections were removed for the
calculation of 
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free
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A translation search identified the correct space group enantio-
morph as P4
 
3
 
2
 
1
 
2 and placed one molecule in the asymmetric
unit. This solution was fixed and used to place the second mole-
cule in the asymmetric unit. The two molecules are related by an
approximate twofold noncrystallographic axis. Rigid body refine-
ment of the molecular replacement solution in XPLOR (data 10–
3.0 Å) yielded 
 
R
 
free
 
 5 
 
40.2%, 
 
R
 
work
 
 5 
 
39.6%.
Refinement was carried out using version 3.851 of XPLOR
(28). A bulk solvent correction was calculated to allow the inclu-
sion of data from 20 Å resolution in the refinement procedure.
Cycles of manual model building in O (29) and refinement in
XPLOR were carried out, during which DR2 polymorphic resi-
dues and the MBP peptide were built into the model and data
was included to 2.6 Å. The refinement protocol involved posi-
tional refinement with noncrystallographic symmetry restraints,
group B factor refinement for data from 20 to 3.0 Å resolution,
and restrained individual B factor refinement for data from 20 to
2.6 Å resolution. The model was built into 2Fo-Fc and Fo-Fc elec-
tron density maps. Maps were improved by solvent flattening and
averaging across the noncrystallographic twofold symmetry axis.
The peptide (P-4 to P9) was built into clear, unambiguous den-
sity when 
 
R
 
free
 
 5 
 
32.5% and 
 
R
 
work
 
 5 
 
25.9%; after addition of the
peptide, 
 
R
 
free
 
 5 
 
28.1% and 
 
R
 
work
 
 5 
 
24.6%. Crystallographic re-
straints were lifted for the final two rounds of refinement. The fi-
nal model (
 
R
 
free
 
 
 
5 
 
26.6%, 
 
R
 
work
 
 
 
5 
 
23.4%) contains 768 residues,
50 water molecules, and 2 sugar molecules (attached to residue
Asn 
 
a
 
118 of both NCS-related molecules). No density was ob-
served for the covalent linker. Electron density at the COOH ter-
minus of the peptide (P10 and P11) is weak, indicating that this re-
gion of the peptide is partially disordered. Analysis of 
 
f
 
 
 
c
 
 angles
shows that 85.9% of residues have most favored angles, 12.9% (87
residues) have additionally allowed angles, 0.7% (5 residues) have
generously allowed angles, and 0.3% (2 residues) have disallowed
angles (30). Refinement statistics are shown in Table 1.
 
Results
 
Determination of the Structure of HLA-DR2–MBP Peptide
Complex.
 
The structure of HLA-DR2 complexed with a
peptide from human MBP (residues 85–99) was deter-
mined to 2.6 Å resolution by x-ray crystallography (see
Materials and Methods). The complex was produced using
a Baculovirus insect cell expression system with the MBP
peptide covalently linked to the NH2 terminus of the ma-
ture DR2 b chain, as described by Kozono et al. for mu-
rine MHC class II molecules (24). The protein also in-
cluded COOH-terminal leucine zipper dimerization
domains that were proteolytically cleaved before crystalli-
zation (23). The complex crystallized in a tetragonal space
group (P43212) with two molecules per asymmetric unit.
The two molecules are related by an approximate twofold
noncrystallographic symmetry axis (177.58) resulting in the
formation of a dimer similar to that previously observed for
HLA-DR1 and HLA-DR3 (27, 31, 32). Crystallographic
statistics are shown in Table 1.
General Features of the HLA-DR2 Peptide-binding Site.
HLA-DR2 differs from HLA-DR4, which is associated
with susceptibility to rheumatoid arthritis, at 10 positions
within the b1 domain (Table 2, reference 33). These poly-
morphisms affect the specificity of the P1, P4, P6, P7, and
P9 pockets. Of particular importance is the contribution of
DRb71 to the shape and charge of the P4 pocket, as dis-
cussed below. The MBP peptide is bound in the binding
groove of DR2 with peptide side chains P1, P4, P6, and P9
occupying pockets within the groove (Fig. 1 A). The P1
and P4 pockets are occupied by valine 89 and phenylala-
nine 92, respectively, of the MBP(85–99) peptide. Peptide
binding experiments with single amino acid analogues had
demonstrated that these two residues represent the main
anchor residues for DR2 binding. Residues P2, P3, and P5
(histidine, phenylalanine, and lysine) were identified as ma-
jor TCR contact residues for human MBP-specific T cell
clones (17), and in the crystal structure reported here were
observed to be solvent exposed and accessible for recogni-
tion by TCR (Fig. 1, B and D).
Overall Conformation of the HLA-DR2–bound MBP Pep-
tide. The model for the MBP peptide (85–99) includes
residues 86–99 on one DR2 molecule and residues 85–98
on the second DR2 molecule in the asymmetric unit of the
crystal (Fig. 2 B, yellow and blue, respectively). Electron
density is weak for residues P10 and P11 of the peptides,
suggesting that the COOH termini of the two peptides are
partially disordered (Fig. 2 A). A crystal contact between
peptide residue P-3 in one molecule and P5 from a mole-
cule with related symmetry stabilizes the NH2 terminus of
one peptide, enabling P-4 to be included in the model for
this peptide and P5 lysine to be included in the model for
the other peptide. Analysis of MBP-specific T cell clones
demonstrated that truncation of the P-4 residue (glutamic
acid) greatly reduced the stimulatory capacity of the MBP
peptide for some of the human T cell clones, indicating
that the peptide NH2 terminus may interact with the TCR
(17). However, the arching up of residues P-3 and P-4 in
the DR2/MBP peptide structure may not represent the
position of these residues in a HLA-DR2–MBP-peptide–
TCR complex, but instead a conformation stabilized by
the crystal contact. The two noncrystallographically related
Table 2. DRb Chain Residues that Differ between HLA-DR2 
and HLA-DR4
DRb chain residue Pocket HLA-DR2 HLA-DR4
(DRB1*1501) (DRB1*0401)
9 P9 Trp Glu
11 P6 Pro Val
13 P6,P4 Arg His
33 – Asn His
37 – Ser Tyr
47 P7 Phe Tyr
67 – Ile Leu
71 P7, P4 Ala Lys
86 P1 Val Gly
96 – Gln Tyr1514 Crystal Structure of HLA-DR2
peptides vary slightly in conformation from P6 to P10,
where they are influenced by different crystal contacts to
the b2 helix. Specifically, for one molecule in the asym-
metric unit there is a crystal contact of Arg a50 on a sym-
metry related molecule with Asp b66, Gln b64, Tyr b60,
and P6 Ile.
The overall conformation of the MBP peptide in the
DR2 binding groove is similar to that observed for other
HLA-DR–peptide complexes (27, 31, 32, 34; Fig. 3). Su-
perposition of MHC class II peptides shows that the main
chain conformation is highly conserved for the NH2-ter-
minal segment of these peptides (P-1 to P4); this segment
carries the main DR2 anchor residues (P1 and P4) as well
as important TCR contact residues of the MBP peptide
(histidine and phenylalanine at P2 and P3, as well as lysine
at P5). The conformation of MHC class II–bound peptides
is more divergent towards the COOH-terminal segment
(P6–P10), as described in Dessen et al. (34). Fig. 3 shows
that the COOH terminus of the MBP peptide is positioned
higher in the peptide binding groove than other human
and murine peptides.
HLA-DR2 Binding and TCR Contact Residues in the NH2
Terminus of the MBP Peptide. The NH2 terminus of the
peptide (P-3 to P4) is held in the DR2 peptide binding
groove by a conserved network of hydrogen bonds (27).
Residue P-3 of the peptide is stabilized by an additional
hydrogen bond from the NH of the P-3 side chain to Ser
a53 Og. Valine at the P1 position of the MBP peptide oc-
cupies the hydrophobic P1 pocket. Val b86 at the base of
the P1 pocket results in a smaller P1 pocket than that ob-
served for DR1 and DR4 (Gly at b86), creating a hydro-
phobic pocket identical to that reported for DR3 (31),
Figure 1. Overall structure of the HLA-DR2–MBP peptide complex. (A and B) Top and side view of the HLA-DR2–MBP peptide complex. 14 res-
idues are included for the MBP peptide (P-3 Asn to P11 Arg). P1 Val and P4 Phe occupy the hydrophobic P1 and P4 pockets, respectively, and serve as
primary anchor residues of the MBP peptide. Peptide atoms are shown as ball-and-stick. (C) View of the large P4 pocket of HLA-DR2 that is occupied
by P4 Phe of the MBP peptide. Gln b70 is positioned over P4 Phe of the peptide. (D) TCR contact residues of the MBP peptide. P2 His, P3 Phe, and
P5 Lys that were previously shown to be important for TCR recognition of the MBP peptide are prominent, solvent exposed residues. Figure was drawn
with GRASP (55).1515 Smith et al.
which can bind aliphatic amino acids and phenylalanine
(35). Residue P2 His of the MBP peptide packs against His
b81, whereas side chain P3 Phe nestles in a hydrophobic
shelf of the a2 helix. The side chains of P2 His and P3 Phe
are both accessible for interaction with the TCR (Fig. 1,
A–D). The peptide main chain from P-3 to P4 of the MBP
peptide superimposes almost identically with the main
chain of other peptides bound to human DR molecules
(Fig. 3), probably because these DR molecules are identical
in this part of the groove; the only polymorphism in this
region is at position b86 at the bottom of the P1 pocket.
The Large, Primarily Hydrophobic P4 Pocket of HLA-DR2.
In the HLA-DR2–MBP peptide complex, the P4 pocket is
occupied by an aromatic side chain (Phe) that makes an im-
portant contribution to the binding of the MBP peptide.
The P4 pocket of HLA-DR2 has a preference for aromatic
as well as aliphatic residues. Binding is also observed with
analogues of the MBP peptide that carry a substitution by
histidine, arginine, lysine, glutamine or asparagine at P4;
substitution by aspartic acid is not tolerated (reference 17
and Pyrdol, J., and K.W. Wucherpfennig, unpublished
data). In contrast, HLA-DR4 has a preference for nega-
tively charged residues, hydrogen bond donors, and some
aliphatic amino acids at P4; peptides with aromatic or posi-
tively charged residues at P4 bind poorly (36, 37). DR2
and DR4 differ only at two positions in the P4 pocket, b71
(Ala in DR2, Lys in DR4) and b13 (Arg in DR2, His in
DR4) (Table 2 and Fig. 4).
The structural basis for this side chain specificity is clear
from the DR2–MBP structure, which reveals a large, pre-
dominantly hydrophobic P4 pocket (Figs. 1 C and 5 A).
The pocket is lined by two aromatic MHC side chains, Tyr
b78 and Phe b26, as well as side chains Gln b70, Ala b71,
Asp b28, and Arg b13. The polymorphism at position 71
in DR2 (Ala) appears to be most important in creating the
available space for the P4 aromatic side chain (Phe) of the
MBP peptide. The presence of negatively charged Asp b28
at the base of the pocket would allow the binding of posi-
tively charged side chains but be unfavorable for the bind-
ing of negatively charged side chains.
In contrast, the P4 pocket of DR4 is smaller and carries a
positive charge at DRb71. In the crystal structure of DR4
with a bound type II collagen peptide, a salt bridge was
present between an aspartic acid residue of the peptide and
Lys b71 (reference 34; Fig. 5 B). Since the majority of
DRB1 alleles encode lysine, arginine, or glutamic acid at
DRb71 (33), the binding of aromatic side chains is an im-
portant aspect of the DR2 peptide binding specificity.
Figure 2. (A) Electron density of the MBP peptide bound to HLA-DR2. Fo-Fc omit map of the peptide. The COOH terminus of the peptide (P10,
P11) is partially disordered. (B) Superposition of the two MBP peptides in the asymmetric unit. The model for the MBP peptide includes residues P-3 to
P11 and P-4 to P10 for the two copies in the asymmetric unit (yellow and blue, respectively). The peptide backbones superimpose in the P-1 to P4 seg-
ment and are more divergent in the COOH-terminal segment due to different crystal contacts to the b2 helix. A crystal contact between peptide residue
P-3 in one molecule and P5 from a symmetry related molecule stabilizes the NH2 terminus of one peptide, enabling P-4 to be included in the model for
this peptide and P5 Lys to be included in the model for the other peptide. Figure was drawn with RIBBONS (56).1516 Crystal Structure of HLA-DR2
plained by the DR2–MBP crystal structure, which reveals a
predominantly negatively charged pocket (Fig. 1, A and
C). Available space in the polar P6 pocket is limited com-
pared with other DR alleles due to the presence of poly-
morphic side chain Arg b13. This prevents P6 Asn from
binding as deeply in the P6 pocket as previously observed
for DR–peptide complexes and is at least partially responsi-
ble for the raised position of the MBP peptide COOH ter-
minus within the peptide binding groove.
Peptide side chains P7 Ile and P9 Thr do not fully oc-
cupy the available space in their binding pockets (Fig. 1, A
and C). Two water molecules fill the space usually occu-
pied by the P7 side chain. It would appear to be more en-
ergetically favorable for the polar P7 pocket to be filled
with water molecules than the hydrophobic P7 Ile peptide
side chain. The water molecules are satisfying hydrogen
bonding requirements (particularly of residues Asp b28 and
Tyr b30) that could not be satisfied by P7 Ile. The hydro-
phobic DR2 P9 pocket is identical to the DR1 P9 pocket.
However, the MBP peptide P9 Thr does not fully occupy
the available space in the P9 pocket (Fig. 1, A and B). It is
possible that this is due to the suboptimal nature of the P9
anchor residue since substitution of the P9 position results
in a modest increase of the binding affinity of the MBP
peptide (reference 17 and Pyrdol, J., and K.W. Wucherpfen-
nig, unpublished data). Also, the position of P9 Thr could
be due to the overall raised position of the COOH termi-
nus of the MBP peptide within the DR2 binding groove
that prevents P9 Thr from binding more deeply in the P9
Figure 3. Superposition of
human and murine MHC class
II–bound peptides. (A) Superpo-
sition of the two MBP peptides
in the asymmetric unit (blue) and
peptides bound to other human
MHC class II molecules (yellow).
Human MHC class II peptides:
DR1–HA, DR3–CLIP, DR4–
type II collagen (27, 32, 34). The
conformation of the peptide
backbone is highly conserved in
the P-1 to P4 segment and di-
vergent in the COOH-terminal
segment. (B) Superposition of the
two MBP peptides in the asym-
metric unit (blue) and murine
MHC class II peptides. I-Ek pep-
tides (I-Ek/Hb, I-Ek/Hsp) are in
red and I-A peptides (I-Ak/HEL,
I-Ad/Ova, I-Ad/HA) are in gray
(39–41). The conformation of
the peptide backbone is similar
between HLA-DR and I-E mol-
ecules in the P1 to P4 segment.
I-A peptides are bound deeper in
the peptide binding site than DR
or I-E peptides. Superpositions
were carried out using the a1
and  b1 domains of MHC class II
molecules. Figure was drawn
with RIBBONS (56).
The DRb71 polymorphism, which is not solvent ex-
posed, has also been reported to affect TCR recognition of
DR–peptide complexes (38). The indirect effect of DRb71
on TCR recognition can be understood by comparison of
the P4 pockets of DR2 and DR4 (Fig. 5), which shows
that solvent-exposed MHC residue Gln b70 differs mark-
edly in its position between the two structures. In the
DR2–MBP peptide structure, Gln b70 is in a horizontal
position relative to the peptide binding site while it is
pointing up in the DR4–type II collagen peptide structure.
These results indicate that DRb71 can have an indirect ef-
fect on TCR recognition by altering the characteristics of
the P4 pocket and the interactions that a bound peptide an-
chor residue can make with solvent accessible side chains.
COOH Terminus of the MBP Peptide. The COOH-ter-
minal half of the peptide main chain, from P5 to P10, is
positioned higher in the groove than peptides bound to
DR1, DR3, and DR4 (Fig. 3). P6 Asn of the MBP peptide
binds in a polar P6 pocket (Fig. 1, A and C), forming part
of a complex hydrogen bonding network that includes
conserved MHC side chains Glu a11, Asn a69, Asn a62,
Asp a66, a water molecule, and polymorphic residue Arg
b13. The nature of this pocket is likely to be conserved in
all human DR and mouse I-E molecules and has been sug-
gested to determine the pH dependency of MHC class II
peptide loading (39). Single amino acid substitutions of the
MBP peptide show that analogues with a negatively
charged side chain bind poorly at P6 (Pyrdol, J., and K.W.
Wucherpfennig, unpublished data). This is readily ex-1517 Smith et al.
and substitutions at P6, P7, or P9 of the MBP peptide had
relatively little effect on DR2 binding. Taken together,
these data indicate that the peptide COOH terminus does
not contribute significantly to the overall binding energy of
the MBP peptide to HLA-DR2.
Discussion
Previous studies demonstrated that P2 His, P3 Phe, and
P5 Lys are important residues for TCR recognition of the
DR2–MBP peptide complex (17, 42). The DR2–MBP
crystal structure shows that these peptide side chains are
solvent exposed (Fig. 1 D) and available for TCR recogni-
tion. Comparison with the recently published high resolu-
tion crystal structures of human MHC class I–peptide–
TCR complexes (43, 44) suggests that P5 Lys would bind
in a pocket formed between the TCR Va and Vb domains
and may form a hydrogen bond to negatively charged resi-
due(s) in the CDR3 loop of a and/or b.
P3 Phe is a primary TCR contact residue for human
MBP(85–99)-specific T cell clones since substitution of P3
Phe reduces/abolishes T cell activation without affecting
DR2 binding. Some T cell clones are highly specific for
this position since substitution by any natural amino acid
greatly reduces or abolishes T cell activation. The NH2-
terminal segment of the MBP peptide makes a contribution
to TCR recognition since truncation of P-4 and P-3
greatly diminishes TCR recognition by some DR2–MBP-
specific T cell clones without affecting DR2 binding. In
contrast, the COOH-terminal segment of the peptide is
not important for recognition by these T cell clones since
almost all substitutions at P7, P8 and P9 are tolerated (ref-
erence 17 and Pyrdol, J., and K.W. Wucherpfennig, un-
published data). The degenerate HLA-DR2 binding motif
as well as the requirement for sequence similarity/identity
at a limited number of peptide residues that interact with
the TCR account for the observation that microbial pep-
tides that are quite diverse in their primary sequence can
activate human MBP-specific T cell clones (42, 45).
A large, primarily hydrophobic P4 pocket was found to
be a prominent feature of the DR2 peptide binding site.
This pocket is occupied by a phenylalanine of the MBP
peptide that makes an important contribution to the bind-
ing of the MBP peptide to DR2. The presence of an ala-
nine at the polymorphic DRb71 position creates the nec-
essary room for the binding of an aromatic side chain in the
P4 pocket. The binding of aromatic side chains by the P4
pocket of DR2 is also facilitated by two aromatic residues
of the P4 pocket (b26 Phe and b78 Tyr, of which b26 is
polymorphic) (Fig. 5 A). The presence of alanine at
DRb71 is unusual for DRB1 alleles and has only been ob-
served for DR2 alleles (DRB1*1501-DRB1*1506) and
DRB1*1309; all other known DRB1 alleles encode lysine,
arginine, or glutamic acid at this position (33). In Cauca-
sians, DRB1*1501 is the most common DR2 haplotype; it
is also the haplotype that confers an increased susceptibility
to the development of MS. It is not known if other DR2
alleles confer susceptibility to MS because they are rela-
Figure 4. DRb chain residues that differ between HLA-DR2 and
HLA-DR4. The HLA-DR2 peptide binding groove is viewed from
above with the MBP peptide represented in yellow as a ball-and-stick
model. Polymorphic side chains that are different between DR2 and
DR4 are shown and color coded according to their proximity to a pep-
tide binding pocket. Color coding: pink, P1 pocket; red, P4 pocket; blue,
P6 pocket; magenta, P7 pocket; green, P9 pocket. Arg b13 (red) forms part
of both the P4 and P6 pockets. Asn b33 and Gln b96 are not located
within the immediate vicinity of the peptide and are not included in the
figure. Figure was drawn with RIBBONS (56).
pocket. The raised position of the peptide COOH termi-
nus compared with other DR–peptide complexes therefore
may be due to a relatively poor fit of the peptide side chains
to the available pockets.
A contribution by the covalent linker on the position of
the COOH terminus of the peptide cannot be excluded. In
this respect it is interesting to compare the DR2–MBP
structure with the mouse I-Ek, I-Ak, and I-Ad crystal struc-
tures that were also determined with peptides covalently
linked to the NH2 terminus of the class II b chain. In the I-Ek
structures, the covalent linker is ordered, positions P9 and
P10 of the peptide are not raised, and anchor residue P9
Lys binds deep in the P9 pocket (39). However, for the
peptides bound to the I-A structures, the linkers are disor-
dered, the P9 anchor residue is small, and the peptide
COOH terminus is raised in the groove (40, 41). These re-
sults suggest the possibility that in the case where the P9
residue is small, the presence of a covalent linker may influ-
ence the position of the peptide COOH terminus.
In addition to the partial occupancy of the P7 and P9
pockets, the hydrogen bonding pattern at the COOH ter-
minus of the MBP peptide is unusual. Hydrogen bonds
from conserved MHC residue Trp b61 to peptide P8 O
and residue a69 to peptide P9 N and P7 O are not formed.
Similarly, the hydrogen bond from Trp b61 to P8 O is ab-
sent in the I-Ak/hen egg lysozyme structure (40). The ob-
servation that the P7 and P9 pockets are only partially oc-
cupied is consistent with peptide binding studies. The
COOH terminus of the MBP peptide could be truncated
to P7 Ile without a significant loss of binding affinity (17),1518 Crystal Structure of HLA-DR2
tively uncommon in Europe and Northern America,
where the highest prevalence of MS is observed. Since the
DRB1 gene is in linkage disequilibrium with the DRB5
gene as well as DQA/DQB genes, both DR and DQ mol-
ecules encoded by this haplotype may contribute to the
pathogenesis of MS (9).
The P4 pocket of HLA-DR makes an important contri-
bution to susceptibility to other human autoimmune dis-
eases. This is readily explained by the fact that the P4 pocket
is the most polymorphic pocket of the HLA-DR binding
site. For example, an HLA-DR4 allele (DRB1*0402) that
is associated with susceptibility to pemphigus vulgaris, an
autoimmune disease of the skin, differs from a rheumatoid
arthritis associated allele (DRB1*0404) only at three posi-
tions, DRb67, -70, and -71. In the pemphigus vulgaris as-
sociated allele, DRb70 and -71 of the P4 pocket carry neg-
ative charges (aspartic acid and glutamic acid, respectively).
In contrast, glutamine and lysine/arginine are present at
DRb70 and -71, respectively, in rheumatoid arthritis–asso-
ciated alleles (DRB1*0401 and *0404) (2, 37, 46–49). A
peptide from type II collagen that is immunodominant for
murine type II collagen–specific T cells has been identified
in HLA-DR1 and HLA-DR4 transgenic mice; this peptide
carries an aspartic acid residue at the P4 position (50, 51).
The structural characteristics of the DR2 binding site
may also help to explain the binding of Cop 1 to DR2 and
other DR molecules. Cop 1 is a random copolymer com-
posed of l-alanine, l-lysine, l-glutamic acid, and l-tyrosine
in a molar ratio of 6.0:4.7:1.9:1.0 that has shown a certain
degree of clinical efficacy in relapsing-remitting MS (52,
53). Cop 1 was found to bind to a number of different DR
molecules and to compete with the binding of peptides
(54). Since DR1 (DRA, DRB1*0101) and DR4 (DRA,
DRB1*0401) have large P1 pockets (Gly at b86), tyrosine
may serve as a P1 anchor for DR1 and DR4 binding. In
contrast, the P1 pocket of HLA-DR2 is too small (Val at
b86) to accommodate a tyrosine side chain and too hydro-
phobic to accommodate lysine or glutamic acid. It is more
likely that a tyrosine residue of Cop 1 could be accommo-
dated in the P4 pocket of DR2 and act as an anchor residue
for Cop 1 binding.
The structural information on the P4 pocket of different
DR molecules may be useful for the development of small
organic molecules that inhibit peptide presentation by DR
molecules associated with particular autoimmune diseases.
Introduction of particular moieties in the P4 pocket may
allow specificity for certain DR molecules to be intro-
duced. For example, ligands with large, aromatic substitu-
ents in the P4 pocket may be relatively selective for DR2,
whereas a negatively charged substituents may introduce a
certain degree of specificity for rheumatoid arthritis–associ-
ated DR4 molecules.
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Figure 5. Comparison of the P4 pockets of HLA-DR2 and HLA-DR4. (A) P4 pocket of HLA-DR2. P4 Phe of the MBP peptide occupies a large,
predominantly hydrophobic pocket in HLA-DR2. P4 Phe interacts with another aromatic residue, Phe b26. The fact that the polymorphic DRb71 res-
idue is an alanine (blue) creates the necessary space for the aromatic peptide side chain. Gln b70 is in an approximately horizontal position. (B) P4 pocket
of HLA-DR4. DRb71 is a lysine (blue) and makes a salt bridge to P4 Asp of the type II collagen peptide (34). Gln b70 is rotated to a more upward point-
ing position. Figure was drawn with RIBBONS (56).1519 Smith et al.
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